HRP20221323T1 - Protutijela protiv signalno-regulacijskog proteina alfa i postupci njihove uporabe - Google Patents

Protutijela protiv signalno-regulacijskog proteina alfa i postupci njihove uporabe Download PDF

Info

Publication number
HRP20221323T1
HRP20221323T1 HRP20221323TT HRP20221323T HRP20221323T1 HR P20221323 T1 HRP20221323 T1 HR P20221323T1 HR P20221323T T HRP20221323T T HR P20221323TT HR P20221323 T HRP20221323 T HR P20221323T HR P20221323 T1 HRP20221323 T1 HR P20221323T1
Authority
HR
Croatia
Prior art keywords
seq
amino acid
acid sequence
sequence
hvr
Prior art date
Application number
HRP20221323TT
Other languages
English (en)
Inventor
Jaume Pons
Bang Janet Sim
Hong Wan
Tracy Chia-Chien Kuo
Steven Elliot KAUDER
William Don Harriman
Shelley IZQUIERDO
Original Assignee
ALX Oncology Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALX Oncology Inc. filed Critical ALX Oncology Inc.
Publication of HRP20221323T1 publication Critical patent/HRP20221323T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)

Claims (20)

1. Izolirano protutijelo koje se veže na izvanstaničnu domenu ljudskog polipeptida SIRP-α, pri čemu se protutijelo veže na izvanstaničnu domenu ljudskog polipeptida SIRP-α v1, izvanstaničnu domenu ljudskog polipeptida SIRP-α v2, izvanstaničnu domenu majmunskog polipeptida SIRP-α, te izvanstaničnu domenu mišjeg polipeptida SIRP-α; i pri čemu protutijelo sadrži: (a) varijabilnu domenu teškog lanca (VH), koja sadrži: (i) HVR-H1 slijed koji sadrži aminokiselinski slijed X1X2AX3S, pri čemu je X1 S ili T; X2 je N, Y, H ili D; i X3 je M, L ili V (SEQ ID NO:297); (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISX1X2X3X4X5X6YYX7X8SX9KG, pri čemu je X1 A ili S; X2 je G, S, ili je odsutan; X3 je S, D ili G; X4 je G ili S; X5 je D, S ili G; X6 je T ili A; X7 je P, G, V, I, A ili S; X8 je A, D ili G; i X9 je V ili M (SEQ ID NO:298); i (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193); i (b) varijabilnu domenu lakog lanca (VL), koja sadrži: (i) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGX1X2X3SX4YYX5, pri čemu je X1 D, G, S, I, ili je odsutan; X2 je S, W, G, Y, D, ili je odsutan; X3 je S, Y, T ili D; X4 je H, T, S ili Y; i X5 je G ili A (SEQ ID NO:299); (ii) HVR-L2 slijed koji sadrži aminokiselinski slijed SDX1X2RPX3, pri čemu je X1 D ili N; X2 je E, K ili Q; i X3 je S ili P (SEQ ID NO:300); i (iii) HVR-L3 slijed koji sadrži aminokiselinski slijed X1X2YDX3X4X5YX6NX7, pri čemu je X1 G ili A; X2 je G ili A; X3 je G, Y, Q, S ili A; X4 je S, R ili T; X5 je T ili S; X6 je A, I, V, L ili T; i X7 je T, A, D ili P (SEQ ID NO:301).
2. Protutijelo u skladu s patentnim zahtjevom 1, pri čemu je protutijelo humanizirano protutijelo kojeg proizvodi ili ga se dobiva iz kokoši.
3. Protutijelo u skladu s patentnim zahtjevom 1 ili 2, pri čemu protutijelo blokira vezanje između izvanstanične domene ljudskog polipeptida SIRP-α i domene IgSF ljudskog polipeptida CD47.
4. Protutijelo u skladu s patentnim zahtjevom 1 ili 2, pri čemu protutijelo sadrži: (a) varijabilnu domenu teškog lanca (VH), koja sadrži: (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SX1AX2S, pri čemu je X1 N ili Y; i pri čemu X2 je M, L ili V (SEQ ID NO:302); (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISX1GX2X3DTYYX4X5SVKG, pri čemu je X1 A ili S; X2 je G ili je odsutan; X3 je S ili G; X4 je P, G ili V; i X5 je A ili D (SEQ ID NO:303); i (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193); i (b) varijabilnu domenu lakog lanca (VL), koja sadrži: (i) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGX1YSSYYYA, pri čemu je X1 S ili A (SEQ ID NO:304); (ii) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336); i (iii) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172).
5. Protutijelo u skladu s patentnim zahtjevom 4, pri čemu VH domena sadrži: (a) (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SNAMS (SEQ ID NO:194), SNAVS (SEQ ID NO:271) ili SNALS (SEQ ID NO:318), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISAGGSDTYYPASVKG (SEQ ID NO:195), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193); (b) aminokiselinski slijed koji je najmanje 90 % istovjetan aminokiselinskom slijedu SEQ ID NO:135, 263, 264 ili 330; (c) (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SNAMS (SEQ ID NO:194), SNAVS (SEQ ID NO:271) ili SNALS (SEQ ID NO:318), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISSGSDTYYGDSVKG (SEQ ID NO:197), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193); (d) aminokiselinski slijed koji je najmanje 90 % istovjetan aminokiselinskom slijedu SEQ ID NO:137, 265, 266 ili 331; (e) (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SYAMS (SEQ ID NO:200), SYAVS (SEQ ID NO:272) ili SYALS (SEQ ID NO:319), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISSGGDTYYVDSVKG (SEQ ID NO:201), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193); ili (f) aminokiselinski slijed koji je najmanje 90 % istovjetan aminokiselinskom slijedu SEQ ID NO:139, 267, 268 ili 332.
6. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 4-5, pri čemu VL domena sadrži: (a) (i) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGSYSSYYYA (SEQ ID NO:170), (ii) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336), te (iii) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172); (b) aminokiselinski slijed koji je najmanje 90 % istovjetan aminokiselinskom slijedu SEQ ID NO:252; (c) (i) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGAYSSYYYA (SEQ ID NO:261), (ii) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336), te (iii) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172); ili (d) aminokiselinski slijed koji je najmanje 90 % istovjetan aminokiselinskom slijedu SEQ ID NO:262; pri čemu VL domena može sadržavati slijed FW1—HVR-L1—FW2—HVR-L2—FW3—HVR-L3—FW4 (od N-kraja do C-kraja), pri čemu FW1 sadrži aminokiselinski slijed SYELTQPPSVSVSPGQTARITC (SEQ ID NO:314), FW2 sadrži aminokiselinski slijed WYQQKPGQAPVTLIY (SEQ ID NO:315), FW3 sadrži aminokiselinski slijed NIPERFSGSSSGTTVTLTISGVQAEDEADYYC (SEQ ID NO:316), te FW4 sadrži aminokiselinski slijed FGGGTKLTVL (SEQ ID NO:317); i pri čemu protutijelo može sadržavati konstantno područje lakog lanca koje sadrži aminokiselinski slijed SEQ ID NO:325, 326 ili 426.
7. Protutijelo u skladu s patentnim zahtjevom 4, pri čemu (a) VH domena sadrži (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SNAMS (SEQ ID NO:194), SNAVS (SEQ ID NO:271) ili SNALS (SEQ ID NO:318), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISAGGSDTYYPASVKG (SEQ ID NO:195), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193), a VL domena sadrži (iv) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGSYSSYYYA (SEQ ID NO:170), (v) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336), te (vi) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172); (b) VH domena sadrži (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SNAMS (SEQ ID NO:194), SNAVS (SEQ ID NO:271) ili SNALS (SEQ ID NO:318), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISSGSDTYYGDSVKG (SEQ ID NO:197), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193), a VL domena sadrži (iv) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGSYSSYYYA (SEQ ID NO:170), (v) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336), te (vi) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172); (c) VH domena sadrži (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SYAMS (SEQ ID NO:200), SYAVS (SEQ ID NO:272) ili SYALS (SEQ ID NO:319), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISSGGDTYYVDSVKG (SEQ ID NO:201), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193), a VL domena sadrži (iv) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGSYSSYYYA (SEQ ID NO:170), (v) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336), te (vi) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172); (d) VH domena sadrži (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SNAMS (SEQ ID NO:194), SNAVS (SEQ ID NO:271) ili SNALS (SEQ ID NO:318), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISAGGSDTYYPASVKG (SEQ ID NO:195), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193), a VL domena sadrži (iv) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGAYSSYYYA (SEQ ID NO:261), (v) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336), te (vi) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172); (e) VH domena sadrži (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SNAMS (SEQ ID NO:194), SNAVS (SEQ ID NO:271) ili SNALS (SEQ ID NO:318), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISSGSDTYYGDSVKG (SEQ ID NO:197), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193), a VL domena sadrži (iv) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGAYSSYYYA (SEQ ID NO:261), (v) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336), te (vi) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172); ili (f) VH domena sadrži (i) HVR-H1 slijed koji sadrži aminokiselinski slijed SYAMS (SEQ ID NO:200), SYAVS (SEQ ID NO:272) ili SYALS (SEQ ID NO:319), (ii) HVR-H2 slijed koji sadrži aminokiselinski slijed GISSGGDTYYVDSVKG (SEQ ID NO:201), te (iii) HVR-H3 slijed koji sadrži aminokiselinski slijed ETWNHLFDY (SEQ ID NO:193), a VL domena sadrži (iv) HVR-L1 slijed koji sadrži aminokiselinski slijed SGGAYSSYYYA (SEQ ID NO:261), (v) HVR-L2 slijed koji sadrži aminokiselinski slijed SDDKRPS (SEQ ID NO:336), te (vi) HVR-L3 slijed koji sadrži aminokiselinski slijed GGYDQSSYTNP (SEQ ID NO:172).
8. Protutijelo u skladu s patentnim zahtjevom 1, pri čemu (a) VH domena sadrži aminokiselinski slijed SEQ ID NO:263, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (b) VH domena sadrži aminokiselinski slijed SEQ ID NO:264, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (c) VH domena sadrži aminokiselinski slijed SEQ ID NO:330, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (d) VH domena sadrži aminokiselinski slijed SEQ ID NO:135, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (e) VH domena sadrži aminokiselinski slijed SEQ ID NO:137, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (f) VH domena sadrži aminokiselinski slijed SEQ ID NO:139, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (g) VH domena sadrži aminokiselinski slijed SEQ ID NO:265, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (h) VH domena sadrži aminokiselinski slijed SEQ ID NO:266, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (i) VH domena sadrži aminokiselinski slijed SEQ ID NO:331, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (j) VH domena sadrži aminokiselinski slijed SEQ ID NO:267, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (k) VH domena sadrži aminokiselinski slijed SEQ ID NO:268, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (l) VH domena sadrži aminokiselinski slijed SEQ ID NO:332, a VL domena sadrži aminokiselinski slijed SEQ ID NO:252; (j) VH domena sadrži aminokiselinski slijed SEQ ID NO:263, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (m) VH domena sadrži aminokiselinski slijed SEQ ID NO:264, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (n) VH domena sadrži aminokiselinski slijed SEQ ID NO:330, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (o) VH domena sadrži aminokiselinski slijed SEQ ID NO:265, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (p) VH domena sadrži aminokiselinski slijed SEQ ID NO:266, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (q) VH domena sadrži aminokiselinski slijed SEQ ID NO:331, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (r) VH domena sadrži aminokiselinski slijed SEQ ID NO:267, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (s) VH domena sadrži aminokiselinski slijed SEQ ID NO:268, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (t) VH domena sadrži aminokiselinski slijed SEQ ID NO:332, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (u) VH domena sadrži aminokiselinski slijed SEQ ID NO:135, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; (v) VH domena sadrži aminokiselinski slijed SEQ ID NO:137, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262; ili (w) VH domena sadrži aminokiselinski slijed SEQ ID NO:139, a VL domena sadrži aminokiselinski slijed SEQ ID NO:262.
9. Protutijelo u skladu s patentnim zahtjevom 1 ili 2, pri čemu se protutijelo veže na ljudski polipeptid SIRP-α v1 na jednom ili više aminokiselinskih položaja koje se bira iz skupine koju čine I31, V33, Q52, K53, T67, R69, N70, te K96, prema SEQ ID NO:296; pri čemu izborno: (a) protutijelo se veže na ljudski polipeptid SIRP-α v1 na I31, V33, Q52, K53, T67, R69, N70, te K96, prema SEQ ID NO:296; (b) protutijelo se dodatno veže na ljudski polipeptid SIRP-α v1 na jednom ili više aminokiselinskih položaja koje se bira iz skupine koju čine L30, P32, E54, T62, N71, M72, F74, te R95, prema SEQ ID NO:296; (c) protutijelo se dodatno veže na ljudski polipeptid SIRP-α v1 na L30, P32, E54, T62, N71, M72, F74, te R95, prema SEQ ID NO:296; i/ili (d) ljudski polipeptid SIRP-α v1 sadrži aminokiselinski slijed SEQ ID NO:5, ljudski polipeptid SIRP-α v2 sadrži aminokiselinski slijed SEQ ID NO:6, majmunski polipeptid SIRP-α sadrži aminokiselinski slijed SEQ ID NO:11, a mišji polipeptid SIRP-α sadrži aminokiselinski slijed SEQ ID NO: 7.
10. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-9, pri čemu je protutijelo: (a) monoklonsko protutijelo; ili (b) scFv-Fc protutijelo.
11. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-9, pri čemu protutijelo sadrži Fc područje; pri čemu izborno: (a) protutijelo sadrži aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:320-324; (b) Fc područje je ljudsko Fc područje kojeg se bira iz skupine koju čine Fc područje iz IgG1, Fc područje iz IgG2, te Fc područje iz IgG4; (c) Fc područje uključuje Fc područje ljudskog IgG1 koje sadrži jednu ili više mutacija koje se bira iz skupine koju čine L234A, L235A, G237A, te N297A, prema EU obrojčavanju; (d) Fc područje uključuje Fc područje ljudskog IgG2 koje sadrži jednu ili više mutacija koje se bira iz skupine koju čine A330S, P331S i N297A, prema EU obrojčavanju; (e) Fc područje uključuje Fc područje ljudskog IgG2 koje sadrži mutaciju N297A, prema EU obrojčavanju; (f) Fc područje uključuje Fc područje ljudskog IgG2 koje sadrži mutaciju A330S i/ili P331S, prema EU obrojčavanju; ili (g) Fc područje uključuje Fc područje ljudskog IgG4 koje sadrži jednu ili više mutacija koje se bira iz skupine koju čine S228P, E233P, F234V, L235A, L235E, delG236, te N297A, prema EU obrojčavanju.
12. Protutijelo u skladu s patentnim zahtjevom 1, pri čemu VH domena sadrži aminokiselinski slijed SEQ ID NO: 263, a VL domena sadrži aminokiselinski slijed SEQ ID NO: 252; pri čemu protutijelo dodatno sadrži konstantno područje lakog lanca koje sadrži aminokiselinski slijed SEQ ID NO: 325, 326 ili 426; i pri čemu protutijelo dodatno sadrži aminokiselinski slijed kojeg se bira iz skupine koju čine SEQ ID NO:320-324.
13. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-12, pri čemu: (a) protutijelo je konjugirano s citotoksičnim sredstvom ili biljegom; ili (b) protutijelo je bispecifično protutijelo.
14. Jedan ili više polinukleotida koji kodiraju protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-13.
15. Jedan ili više vektora koji sadrže polinukleotide u skladu s patentnim zahtjevom 14.
16. Jedan ili više stanica domaćina koje sadrže polinukleotide u skladu s patentnim zahtjevom 14 ili vektore u skladu s patentnim zahtjevom 15.
17. Postupak proizvodnje protutijela, gdje se postupak sastoji u uzgoju stanica domaćina u skladu s patentnim zahtjevom 16 na takav način da se proizvodi protutijelo; pri čemu postupak može dodatno uključivati prikupljanje protutijela iz stanice domaćina.
18. Farmaceutski pripravak koji sadrži protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-13 i farmaceutski prihvatljivi nosač.
19. Protutijelo u skladu s bilo kojim od patentnih zahtjeva 1-13, namijenjeno uporabi u (a) postupku liječenja ili odgađanja napredovanja raka kod osobe ili (b) postupku liječenja ili odgađanja napredovanja autoimune bolesti ili upalne bolesti kod osobe, gdje se postupak sastoji u primjeni na osobi djelotvorne količine protutijela.
20. Protutijelo namijenjeno uporabi u skladu s patentnim zahtjevom 19(a), pri čemu postupak dodatno uključuje primjenu na osobi: (a) djelotvorna količina drugog protutijela koje se veže na antigen kojeg eksprimira rak, pri čemu se antigen kojeg eksprimira rak može birati iz skupine koju čine CD19, CD20, CD22, CD30, CD33, CD38, CD52, CD56, CD70, CD74, CD79b, CD123, CD138, CS1/SLAMF7, Trop-2, 5T4, EphA4, BCMA, mucin 1, mucin 16, PTK7, STEAP1, receptor endotelina B, mezotelin, EGFRvIII, ENPP3, SLC44A4, GNMB, nektin 4, NaPi2b, LIV-1A, gvanilil-ciklaza C, DLL3, EGFR, HER2, VEGF, VEGFR, integrin αVβ3, integrin α5β1, MET, IGF1R, TRAILR1, TRAILR2, RANKL, FAP, tenascin, Ley, EpCAM, CEA, gpA33, PSMA, TAG72, mucin, CAIX, EPHA3, folatni receptor α, GD2, GD3, te MHC/peptidni kompleks koji sadrži peptid iz NY-ESO-1/LAGE, SSX-2, protein iz porodice MAGE, MAGE-A3, gp100/pmel17, Melan-A/MART-1, gp75/TRP1, tirozinaza, TRP2, CEA, PSA, TAG-72, nezreli lamininski receptor, MOK/RAGE-1, WT-1, SAP-1, BING-4, EpCAM, MUC1, PRAME, survivin, BRCA1, BRCA2, CDK4, CML66, MART-2, p53, Ras, β-katenin, TGF-βRII, HPV E6 ili HPV E7; ili (b) djelotvorna količina imunoterapijskog sredstva, pri čemu izborno imunoterapijsko sredstvo sadrži drugo protutijelo, te pri čemu se drugo protutijelo može vezati na antigen kojeg se bira iz skupine koju čine PD-1, PD-L1, OX40, CTLA-4, CD137/4-1BB, TNFR2, B7-H3, FZD7, CD27, CCR4, CSF1R, CSF, TIM-3, LAG-3, VISTA, ICOS, CCR2, IDO, A2R, CD39, CD73, TIGIT, CD80, CD47, arginaza, TDO, te PVRIG.
HRP20221323TT 2016-09-21 2017-09-20 Protutijela protiv signalno-regulacijskog proteina alfa i postupci njihove uporabe HRP20221323T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662397752P 2016-09-21 2016-09-21
US201762515480P 2017-06-05 2017-06-05
EP17853838.5A EP3515490B8 (en) 2016-09-21 2017-09-20 Antibodies against signal-regulatory protein alpha and methods of use
PCT/US2017/052592 WO2018057669A1 (en) 2016-09-21 2017-09-20 Antibodies against signal-regulatory protein alpha and methods of use

Publications (1)

Publication Number Publication Date
HRP20221323T1 true HRP20221323T1 (hr) 2022-12-23

Family

ID=61689740

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20221323TT HRP20221323T1 (hr) 2016-09-21 2017-09-20 Protutijela protiv signalno-regulacijskog proteina alfa i postupci njihove uporabe

Country Status (32)

Country Link
US (4) US11401338B2 (hr)
EP (2) EP4119580A1 (hr)
JP (2) JP7181874B2 (hr)
KR (1) KR102601298B1 (hr)
CN (3) CN109862915B (hr)
AU (1) AU2017332285A1 (hr)
BR (1) BR112019003027A2 (hr)
CA (1) CA3034480A1 (hr)
CL (2) CL2019000668A1 (hr)
CO (1) CO2019003809A2 (hr)
DK (1) DK3515490T3 (hr)
ES (1) ES2932602T3 (hr)
GE (2) GEP20237480B (hr)
HR (1) HRP20221323T1 (hr)
HU (1) HUE060170T2 (hr)
IL (2) IL265439B1 (hr)
JO (1) JOP20190009A1 (hr)
LT (1) LT3515490T (hr)
MA (1) MA46290A (hr)
MX (1) MX2019003168A (hr)
MY (1) MY197854A (hr)
PE (1) PE20190575A1 (hr)
PH (1) PH12019500600A1 (hr)
PL (1) PL3515490T3 (hr)
PT (1) PT3515490T (hr)
RS (1) RS63658B1 (hr)
SA (1) SA519401371B1 (hr)
SG (1) SG10201912878UA (hr)
SI (1) SI3515490T1 (hr)
UA (1) UA126281C2 (hr)
WO (1) WO2018057669A1 (hr)
ZA (1) ZA201900937B (hr)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
SG10201912905VA (en) 2015-08-07 2020-02-27 Alx Oncology Inc Constructs having a sirp-alpha domain or variant thereof
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
CA3051318A1 (en) * 2017-02-17 2018-08-23 Ose Immunotherapeutics New uses of anti-sirpg antibodies
AU2018252546A1 (en) * 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
US11292850B2 (en) * 2018-03-21 2022-04-05 ALX Oncology Inc. Antibodies against signal-regulatory protein α and methods of use
EP3778635A4 (en) * 2018-04-09 2022-01-26 Origincell Therapeutics Co., Ltd. ANTI-PD-L1 ANTIBODIES AND ITS USE
US20210047399A1 (en) * 2018-05-08 2021-02-18 Phanes Therapeutics, Inc. Anti-dll3 antibodies and uses thereof
MX2020011828A (es) * 2018-05-25 2021-02-09 Alector Llc Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
CN110577597B (zh) * 2018-06-11 2021-10-22 康诺亚生物医药科技（成都）有限公司 一种阻断CD47和SIRPα相互作用的抗体
CN112673023B (zh) * 2018-07-10 2023-09-12 国立大学法人神户大学 抗SIRPα抗体
WO2020033646A1 (en) * 2018-08-08 2020-02-13 Orionis Biosciences, Inc. SIRP1α TARGETED CHIMERIC PROTEINS AND USES THEREOF
CN110878123B (zh) * 2018-09-05 2022-08-23 华瑞同康生物技术（深圳）有限公司 一种抗tk1原核重组单链抗体及制备方法
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
CN113166245A (zh) * 2018-09-27 2021-07-23 细胞基因公司 SIRPα结合蛋白及其使用方法
SG11202103805SA (en) * 2018-10-17 2021-05-28 Tallac Therapeutics Inc Immunomodulating polynucleotide conjugates and methods of use
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
WO2020102422A1 (en) * 2018-11-14 2020-05-22 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
WO2020099653A1 (en) 2018-11-15 2020-05-22 Byondis B.V. HUMANIZED ANTI-SIRPα ANTIBODIES
WO2020180811A1 (en) * 2019-03-04 2020-09-10 Qilu Puget Sound Biotherapeutics Corporation Anti-sirp-alpha antibodies
US11026973B2 (en) 2019-04-30 2021-06-08 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
MX2021014627A (es) 2019-05-31 2022-01-06 Alx Oncology Inc Polipeptidos de citocinas enmascaradas.
US20200400662A1 (en) * 2019-06-07 2020-12-24 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
BR112021026376A2 (pt) 2019-06-25 2022-05-10 Gilead Sciences Inc Proteínas de fusão flt3l-fc e métodos de uso
AU2020299600A1 (en) * 2019-07-03 2022-01-06 Crystal Bioscience Inc. Anti-CD38 antibody and methods of use thereof
AU2020299305A1 (en) * 2019-07-03 2022-01-06 Crystal Bioscience Inc. Anti-B7-H3 antibody and methods of use thereof
KR102236127B1 (ko) 2019-08-08 2021-04-07 주식회사 하울바이오 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도
CA3102331A1 (en) * 2019-08-20 2021-02-20 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-sirpa antibodies
MX2022002613A (es) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
KR20220085796A (ko) 2019-10-18 2022-06-22 포티 세븐, 인코포레이티드 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
CN110734897A (zh) * 2019-10-31 2020-01-31 浙江蓝盾药业有限公司 杂交瘤细胞株12g6、抗体及其应用
EP4061852A4 (en) * 2019-11-21 2024-03-13 Unity Biotechnology ANTIBODIES TARGETED TO TIE-2 AND METHODS OF USE
US20210154269A1 (en) 2019-11-27 2021-05-27 ALX Oncology Inc. Combination therapies for treating cancer
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
KR20220131918A (ko) 2019-12-24 2022-09-29 카나 바이오사이언스, 인코포레이션 다이아실글리세롤 키나제 조절 화합물
US11692038B2 (en) 2020-02-14 2023-07-04 Gilead Sciences, Inc. Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8)
CA3169523A1 (en) 2020-02-28 2021-09-02 Jaume Pons Transglutaminase-mediated conjugation
KR20210122185A (ko) * 2020-03-31 2021-10-08 웰마커바이오 주식회사 Igsf1에 대한 항체를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 및 이를 이용한 암 치료 방법
KR20230018475A (ko) 2020-06-01 2023-02-07 알렉소 온콜로지 인크. 암 치료용 저메틸화제를 포함하는 병용 요법
US20230174634A1 (en) * 2020-06-10 2023-06-08 Crystal Bioscience Inc. Anti-bdnf antibodies and methods of use thereof
CN116157418A (zh) * 2020-08-05 2023-05-23 晶体生物科学股份有限公司 抗tigit抗体及其使用方法
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
US20220196651A1 (en) * 2020-12-06 2022-06-23 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220363779A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
AU2022284373A1 (en) 2021-06-04 2024-01-04 Boehringer Ingelheim International Gmbh Anti-sirp-alpha antibodies
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2023278377A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
EP4376952A1 (en) * 2021-07-30 2024-06-05 Alector LLC Anti-sirp-alpha antibodies and methods of use thereof
CN116472351A (zh) 2021-08-17 2023-07-21 杭州九源基因工程有限公司 靶向SIRPα的单克隆抗体及其用途
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
WO2023077030A1 (en) 2021-10-29 2023-05-04 Gilead Sciences, Inc. Cd73 compounds
US20240124412A1 (en) 2021-12-22 2024-04-18 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230242508A1 (en) 2021-12-22 2023-08-03 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023154578A1 (en) 2022-02-14 2023-08-17 Sana Biotechnology, Inc. Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
TW202346277A (zh) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ｉｋａｒｏｓ鋅指家族降解劑及其用途
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh) 2022-04-05 2023-12-01 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
WO2023202672A1 (en) * 2022-04-20 2023-10-26 Biosion Inc. Antibodies targeting sirp-alpha and uses thereof
TW202400138A (zh) 2022-04-21 2024-01-01 美商基利科學股份有限公司 Ｋｒａｓ ｇ１２ｄ調節化合物
US20240010701A1 (en) 2022-06-01 2024-01-11 ALX Oncology Inc. Combination therapies for treating urothelial carcinoma
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
KR102584898B1 (ko) * 2022-10-24 2023-10-04 연세대학교 산학협력단 자궁내막암 진단 방법 및 이를 이용한 키트
WO2024105180A1 (en) 2022-11-16 2024-05-23 Boehringer Ingelheim International Gmbh Predictive efficacy biomarkers for anti-sirpa antibodies

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
US5472556A (en) 1993-06-24 1995-12-05 Alfred D. Lobo Co. Flow-through linear transfer system for making a laminate from synthetic resinous sheets
FR2707446B1 (fr) 1993-07-07 1995-08-11 Pouyet Int Dispositif terminal d'interconnexion téléphonique d'abonné.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0914452A2 (en) 1996-06-17 1999-05-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods
GB2333597B (en) 1996-10-29 2001-04-18 Univ Nebraska At Lincoln Method for detecting point mutations in dna utilizing fluorescence energy transfer
US6143559A (en) 1996-11-18 2000-11-07 Arch Development Corporation Methods for the production of chicken monoclonal antibodies
ATE387495T1 (de) 1996-12-03 2008-03-15 Amgen Fremont Inc Vollkommen humane antikörper die egfr binden
GB9626026D0 (en) 1996-12-14 1997-01-29 Zeneca Ltd Chemical compounds
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
EP1048299A1 (en) 1999-04-28 2000-11-02 Faculteit der Geneeskunde van de Vrije Universiteit Method for inhibiting cell functioning for use in anti-inflammatory and anti-tumour therapies
EP1244707A1 (de) * 1999-11-30 2002-10-02 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper gegen signal-regulator-proteine
GB9930706D0 (en) 1999-12-24 2000-02-16 Medical Res Council Composition for inhibiting macrophage activity
US7282556B2 (en) 2001-05-15 2007-10-16 Emory University Polynucleotides and polypeptides relating to the modulation of SIRPα-CD47
CA2513113A1 (en) 2003-01-23 2004-08-05 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
WO2005014653A2 (en) 2003-02-28 2005-02-17 Protein Design Labs, Inc. Humanized chicken antibodies
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US20100215640A1 (en) 2003-04-24 2010-08-26 The University Of North Carolina At Chapel Hill Method for inhibiting cellular activation by insulin-like growth factor-1
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
EP3284756B1 (en) 2005-10-12 2021-05-05 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
WO2009046541A1 (en) 2007-10-11 2009-04-16 University Health Network MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR
ES2740823T3 (es) 2008-01-15 2020-02-06 Univ Leland Stanford Junior Métodos para manipular fagocitosis mediada por CD47
CA2711370C (en) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
CA2717070C (en) 2008-03-04 2019-12-31 Crystal Bioscience Inc. Gel microdrop composition and method of using the same
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2011019844A1 (en) 2009-08-13 2011-02-17 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal cdrs
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
KR101658479B1 (ko) 2010-02-09 2016-09-21 삼성전자주식회사 불휘발성 메모리 장치, 그것의 동작 방법, 그리고 그것을 포함하는 메모리 시스템
JP6199740B2 (ja) 2010-08-27 2017-09-20 ユニバーシティー ヘルス ネットワーク Ｓｉｒｐａ発現に基づく多能性幹細胞に由来する心筋細胞前駆細胞および心筋細胞を濃縮するための方法
US9380769B2 (en) 2011-05-24 2016-07-05 Crystal Bioscience Inc. Transgenic chicken comprising an inactivated immunoglobulin gene
WO2013056352A1 (en) * 2011-10-19 2013-04-25 University Health Network Antibodies and antibody fragments targeting sirp-alpha and their use in treating hematologic cancers
US9394372B2 (en) 2011-10-21 2016-07-19 Crystal Bioscience Inc. In vivo method for generating diversity in a protein scaffold
EP3677678B1 (en) 2011-12-30 2024-01-31 Cellscript, Llc Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect
EP3556206B1 (en) 2012-11-05 2021-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
HUE047221T2 (hu) 2012-12-17 2020-04-28 Trillium Therapeutics Inc A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal
DK3311824T3 (da) 2013-02-05 2020-04-14 Univ Leland Stanford Junior Cd47 målrettede terapier til behandlingen af infektionssygdomme
WO2014149477A1 (en) 2013-03-15 2014-09-25 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-cd47 agents
EP2992089B1 (en) 2013-04-29 2021-09-08 The Board of Trustees of the Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
ES2765483T3 (es) 2013-09-18 2020-06-09 Univ Leland Stanford Junior Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica
US11046763B2 (en) 2014-01-08 2021-06-29 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
US10081680B2 (en) 2014-03-11 2018-09-25 The Board Of Trustees Of The Leland Stanford Junior University Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies
TWI759810B (zh) 2014-08-08 2022-04-01 美商Ａｌｘ腫瘤技術股份有限公司 信號調節蛋白α(signal-regulatory proteinα, SIRP-α)變體構築物及其用途
PL3180363T3 (pl) 2014-08-15 2020-02-28 Merck Patent Gmbh Białka fuzyjne immunoglobulin sirp-alfa
ES2845898T3 (es) 2014-08-26 2021-07-28 Univ Leland Stanford Junior Injerto de células madre con una combinación de un agente dirigido a las células madre y modulación de señalización inmunoreguladora
EP3012271A1 (en) 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
CA2959821A1 (en) 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
AU2016209268B2 (en) 2015-01-21 2021-04-29 The Board Of Trustees Of The Leland Stanford Junior University Macrophages eat cancer cells using their own calreticulin as a guide
WO2016205042A1 (en) 2015-06-16 2016-12-22 The Board Of Trustees Of The Leland Stanford Junior University SIRPα AGONIST ANTIBODY
EP3328402A4 (en) 2015-07-28 2019-04-03 The Trustees Of The University Of Pennsylvania CHIMERIC ANTIGEN RECEPTORS EXPRESSING MODIFIED MONOCYTES / MACROPHAGES AND USES THEREOF
SI3341015T2 (sl) 2015-08-26 2024-03-29 The Board Of Trustees Of The Leland Stanford, Junior University Izboljšana deplecija ciljanih celic z blokado CD47 in imunostimulatornim agonistom
EP4186927A1 (en) 2015-10-21 2023-05-31 Ose Immunotherapeutics Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
JP7077226B2 (ja) 2015-12-11 2022-05-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
EP3442541B1 (en) 2016-04-10 2021-11-17 Georgia State University Research Foundation, Inc. Composition for use in treating cancer
MA44665A (fr) 2016-04-14 2019-02-20 Ose Immunotherapeutics Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques
AU2017248626B2 (en) 2016-04-14 2024-05-09 Ose Immunotherapeutics New anti-SIRPa antibodies and their therapeutic applications
JP6923942B2 (ja) 2016-07-05 2021-08-25 国立大学法人神戸大学 抗腫瘍剤
JP7369620B2 (ja) 2016-08-03 2023-10-26 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー マクロファージ上のＦｃ受容体結合の破壊による抗ＳｌＲＰα抗体療法の効果増強
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
US20180214524A1 (en) 2017-01-30 2018-08-02 The Board Of Trustees Of The Leland Stanford Junior University Non-genotoxic conditioning regimen for stem cell transplantation
AU2018252546A1 (en) 2017-04-13 2019-10-10 Sairopa B.V. Anti-SIRPα antibodies
US11274159B2 (en) 2017-05-16 2022-03-15 Byondis B.V. Anti-SIRPα antibodies
JP7122370B2 (ja) 2017-07-26 2022-08-19 フォーティ セブン， インコーポレイテッド 抗ｓｉｒｐ－アルファ抗体及び関連方法
US11292850B2 (en) 2018-03-21 2022-04-05 ALX Oncology Inc. Antibodies against signal-regulatory protein α and methods of use
MX2020011828A (es) 2018-05-25 2021-02-09 Alector Llc Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
CN112673023B (zh) 2018-07-10 2023-09-12 国立大学法人神户大学 抗SIRPα抗体
US11591390B2 (en) 2018-09-27 2023-02-28 Celgene Corporation SIRP-α binding proteins and methods of use thereof
WO2020102422A1 (en) 2018-11-14 2020-05-22 Arch Oncology, Inc. THERAPEUTIC SIRPα ANTIBODIES
WO2020099653A1 (en) 2018-11-15 2020-05-22 Byondis B.V. HUMANIZED ANTI-SIRPα ANTIBODIES

Also Published As

Publication number Publication date
RU2019111888A (ru) 2020-10-22
SG10201912878UA (en) 2020-02-27
EP4119580A1 (en) 2023-01-18
JP2020503057A (ja) 2020-01-30
PE20190575A1 (es) 2019-04-22
KR102601298B1 (ko) 2023-11-15
HUE060170T2 (hu) 2023-02-28
IL265439B1 (en) 2024-04-01
RS63658B1 (sr) 2022-11-30
CA3034480A1 (en) 2018-03-29
CN109862915A (zh) 2019-06-07
EP3515490A1 (en) 2019-07-31
GEP20237480B (en) 2023-03-27
EP3515490B8 (en) 2022-09-14
CO2019003809A2 (es) 2019-04-30
ZA201900937B (en) 2023-05-31
JOP20190009A1 (ar) 2019-01-27
GEP20237528B (en) 2023-08-10
SI3515490T1 (sl) 2023-06-30
CL2021000704A1 (es) 2021-07-30
US20180105600A1 (en) 2018-04-19
IL265439A (en) 2019-05-30
IL297891B1 (en) 2024-04-01
PL3515490T3 (pl) 2022-12-19
US11401338B2 (en) 2022-08-02
CL2019000668A1 (es) 2019-05-31
SA519401371B1 (ar) 2022-12-04
PT3515490T (pt) 2022-10-18
BR112019003027A2 (pt) 2019-05-14
MX2019003168A (es) 2019-06-10
MY197854A (en) 2023-07-20
DK3515490T3 (da) 2022-10-24
JP2022003031A (ja) 2022-01-11
EP3515490A4 (en) 2020-04-29
CN117946268A (zh) 2024-04-30
US20220002434A1 (en) 2022-01-06
MA46290A (fr) 2019-07-31
US20210363269A1 (en) 2021-11-25
IL297891A (en) 2023-01-01
US11242404B2 (en) 2022-02-08
LT3515490T (lt) 2022-11-10
CN109862915B (zh) 2023-12-12
EP3515490B1 (en) 2022-08-10
JP7181874B2 (ja) 2022-12-01
US20230018821A1 (en) 2023-01-19
RU2019111888A3 (hr) 2020-10-22
CN117756937A (zh) 2024-03-26
UA126281C2 (uk) 2022-09-14
PH12019500600A1 (en) 2019-06-03
WO2018057669A1 (en) 2018-03-29
KR20190052100A (ko) 2019-05-15
AU2017332285A1 (en) 2019-02-14
ES2932602T3 (es) 2023-01-23

Similar Documents

Publication Publication Date Title
HRP20221323T1 (hr) Protutijela protiv signalno-regulacijskog proteina alfa i postupci njihove uporabe
JP2020503057A5 (hr)
Byrne et al. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
AU2016383475B2 (en) Variable regions for NKp46 binding proteins
CN112119097B (zh) 自然杀伤细胞接合抗体融合构建体
HRP20201375T1 (hr) ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
Chen et al. Bispecific antibodies in cancer immunotherapy
JP2018525382A5 (hr)
JP2019500891A5 (hr)
FI3177643T5 (fi) T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä
JP2019524693A5 (hr)
RU2018143439A (ru) Антигенсвязывающие молекулы, содержащие тримерный лиганд семейства tnf и pd1-связывающий фрагмент
AU2015279321A1 (en) Multispecific antigen binding proteins
JP2017504578A5 (hr)
CA3159904A1 (en) Multispecific antibody
RU2020102662A (ru) Мультиспецифические антитела и способы их получения и применения
CA3201518A1 (en) Bi-functional molecules
US20230114801A1 (en) MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF
US20230002488A1 (en) Guidance and navigation control proteins and method of making and using thereof
JPWO2019005640A5 (hr)
Kafil et al. Immunotargeting and therapy of cancer by advanced multivalence antibody scaffolds
JPWO2019005639A5 (hr)
WO2023147331A1 (en) Bispecific molecule with tunable affinity to a targetted antigen
RU2021120696A (ru) Нацеленные на опухоль агонистические cd28-антигенсвязывающие молекулы